March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Antonio Passaro: What a time to be in thoracic oncology
Mar 29, 2025, 17:00

Antonio Passaro: What a time to be in thoracic oncology

Antonio Passaro, Medical Director at IEO European Institute of Oncology, shared on LinkedIn:

“What a time to be in thoracic oncology! Being at ELCC 25 in Paris made me realize once again how fast lung cancer treatment is evolving.

This year’s congress marked the new landmark for patients with EGFR-mutant lung cancer, with the groundbreaking MARIPOSA study demonstrating a significant overall survival benefit for the combo of amivantamab plus lazertinib

I had the privilege of participating in a controversy session to discuss whether combination therapies should now be considered the new standard in this specific oncogene-driven setting—balancing efficacy, tolerability, and disease characteristics to offer the best possible care for our patients.

The future of lung cancer treatment is changing before our eyes, and this was also the focus of my second talk, dedicated to emerging therapies-particularly ADCs targeting c-MET

Every milestone brings us closer to transforming patient care, with the mission to increase the 5-year survival rate in EGFR-mutant NSCLC.”

Antonio Passaro